logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn treats two coronavirus patients in Phase 2 trial

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan and diagnostic advisor to the group Dr Bruce Patterson tell Proactive the company has enrolled and begun treating the first two patients in its Phase 2 trial of leronlimab for people with mild-to-moderate coronavirus symptoms.

Pourhassan says the company expects enrollment to accelerate this week at multiple clinical sites, while separately, 15 severely ill coronavius patients have been treated with leronlimab so far, primarily in New York.

Quick facts: CytoDyn Inc.

Price: 3.7599 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.95 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to submit request for pre-submission meetings in U.K. for Leronlimab

CytoDyn Inc (OTCQB: CYDY) CEO Nader Pourhassan shared news with Steve Darling from Proactive that the company has started the process of requesting meetings in the U.K. for leronlimab as an HIV treatment as well as for emergency approval of leronlimab for COVID-19 patients with mild-to-moderate...

1 week, 1 day ago

2 min read